Epistem Holdings Plc, the Personalised Medicine and Biotechnology company based in Manchester, has announced the successful presentation and demonstration of the Genedrive® IL28B genotype test at the 49th Annual Meeting of the European Association for the Study of Liver (EASL).
A single nucleotide polymorphism (SNP) predicts the response to hepatitis C (HCV) treatment with interferon. From buccal swabs provided by conference delegates, Epistem demonstrated successful IL28B genotype results in a rapid test using the Genedrive® device.
Genedrive® is a small, handheld ‘Point of Care’ molecular diagnostic device which has been developed by Epistem to provide a major advance in next generation diagnostic and genotype testing. Genedrive® provides a rapid (less than an hour), low cost, simple to use platform enabling high sensitivity DNA genotyping analysis. Genedrive® has broad application across a range of areas including bacterial, viral and fungal identification as well as germline and somatic genotype analysis.
The IL28B Genedrive® test represents the completion of the first stage of a HCV panel test to aid in selection of patients who will respond to treatment with pegylated-interferon and/or ribavirin therapy. Epistem is also developing diagnostic and viral load tests to aid patient clinical and therapy management.
The IL28b test will be made available as a ‘Research Use Only’ product over the coming months and will be followed by subsequent CE-IVD regulatory approval. The IL28B test is the first of a panel of HCV tests that Epistem is developing alongside the European Commission’s 7th Framework Programme for the development of Point of Care HCV tests.
For further details visit www.epistem.co.uk